Cardiovascular diseases (CVDs) are the leading cause of global mortality and morbidity, representing a socioeconomic burden worldwide. Myocardial infarction (MI) is a severe health condition considered as one of the largest contributors to CVDs; following MI, millions of cardiomyocytes die and, owing to cardiac fibroblast recruiting, a scar formation occurs, resulting in impaired cardiac functionality. Cardiac patches have emerged as a potential solution to treat the infarcted myocardium and, recently, focus has increased on the role of cardiac macrophages and extracellular matrix remodelling in response to MI. It is now clear that inflammation driven by immune cells is a crucial step in the progression of post-MI tissue remodelling and scarring which, in turn, limits cardiac function causing a reduction in heart contractility and blood pumping capacity.